Cyxone
0.027
SEK
-35.71 %
CYXO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
-35.71%
+92.86%
-32.5%
-29.87%
-79.58%
-70.52%
-82.97%
-99.31%
-99.33%
-99.48%
cyxone.com/en/investor-relations
Cyxone is a biotechnology company. The company's specialist expertise is found in the development of pharmaceuticals with a focus on plant protein as a base. The pharmaceutical is intended to be used mainly in the treatment of immune-related diseases, and the products are based on cyclotide technology. The purpose is that the pharmaceutical will be used in the treatment of multiple sclerosis and rheumatoid arthritis. Cyxone's head office is located in Malmö.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
CYXO
Daily low / high price
0.027 / 0.05
SEK
Market cap
10.13M SEK
Turnover
95.61K SEK
Volume
2.7M
Financial calendar
Interim report
2024-11-29
Annual report
2025-02-25
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Avanza Pension | 5.8 % | 5.8 % |
| Ivar Nordqvist | 4.2 % | 4.2 % |
| Oxy Pharma AB | 2.8 % | 2.8 % |
| ABBMO Holding AB | 2.4 % | 2.4 % |
| UBS Switzerland AG | 2.3 % | 2.3 % |
| Christian Pettersson | 2.1 % | 2.1 % |
| Göran Ofsén | 1.9 % | 1.9 % |
| Nordnet Pensionsförsäkring | 1.8 % | 1.8 % |
| Nordnet Livsforsikring AS | 1.3 % | 1.3 % |
| Clearstream Banking SA | 1.2 % | 1.2 % |
ShowingAll content types
Cyxone erhåller betalningskrav om knappt 5 miljoner kronor
Cyxone: Delårsrapport 2024-04-01 till 2024-06-30
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools